Kevin Damman is clinical cardiologist and head of the heart transplant and left ventricular assist device program at the University Medical Center Groningen. His research focuses on acute and advanced heart failure, with particular emphasis on the cardiorenal axis.
Current research interests are focused on improving treatment of acute heart failure patients, including early assessment of effect of decongestive therapies, SGLT2-inhibition in (acute) heart failure and the role of the kidney in the process of cardiorenal interaction. He is principle investigator of the EMPA-RESPONSE-AHF study on empagliflozin in acute heart failure and is part of the steering committee of the ADVOR trial investigating acetazolamide in acute heart failure. Dr Damman is associate editor of the European Journal of Heart Failure and serves as official European Society of Cardiology (ESC) Journals Twitter editor. Furthermore, he is member of the working groups on Cardiorenal Dysfunction and Acute Heart Failure from the Heart Failure Association of the ESC.
